A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities.

Trial Profile

A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2011

At a glance

  • Drugs Imiquimod (Primary) ; Methyl aminolevulinate (Primary)
  • Indications Basal cell cancer; Bowen's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top